Peginterferon beta-1a (Peginterferon β-1a) is the first pegylated interferon beta-1a molecule. Peginterferon beta-1a induces cancer cells apoptosis and shows anti-tumor activities in nude mice models. Peginterferon beta-1a can be used for the research of cancer and multiple sclerosis (RMS).
Peginterferon beta-1a (0.001-1000 ng/mL; 5 d) affects cell viability of SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cells[1].
Peginterferon beta-1a (10, 100, and 1,000 ng/mL) induces cell apoptosis[1].
Peginterferon beta-1a (0.1-1.6 mg/kg; s.c. QW/BIW/TIW for 3-4 weeks) inhibits SK-MEL-1, A-375 melanoma and WM-266-4 melanoma cancer growth in xenografts nude mice[1].
References:
[1]. Boccia A, et al. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models. J Interferon Cytokine Res. 2017 Jan;37(1):20-31.